Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Manfredi Rizzo"'
Autor:
Andrej Janez, Emir Muzurovic, Anca Pantea Stoian, Martin Haluzik, Cristian Guja, Leszek Czupryniak, Lea Duvnjak, Nebojsa Lalic, Tsvetalina Tankova, Pawel Bogdanski, Nikolaos Papanas, Josè Silva Nunes, Peter Kempler, Zlatko Fras, Manfredi Rizzo
Publikováno v:
International Journal of Cardiology. 365:8-18
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose
Autor:
Ali A. Rizvi, Djordje S. Popovic, Nikolaos Papanas, Anca Pantea Stoian, Wael Al mahmeed, Amirhossein Sahebkar, Andrej Janez, Manfredi Rizzo
Publikováno v:
Expert Review of Cardiovascular Therapy. 20:515-527
Introduction: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density l
Autor:
Jelena Vekic, Aleksandra Zeljkovic, Marija Mihajlovic, Sanja Vujcic, Azra Guzonjic, Jelena Munjas, Aleksandra Stefanovic, Jelena Kotur-Stevuljevic, Manfredi Rizzo, Natasa Bogavac-Stanojevic, Jelena Gagic, Jelena Kostadinovic
Publikováno v:
Current Vascular Pharmacology. 21
Abstract: Cardiometabolic diseases, such as type 2 diabetes mellitus (DM) and cardiovascular disease (CVD), are a great health concern. The strategies aimed to increase awareness and prevention, in conjunction with timely diagnosis and optimal manage
Autor:
Giulia Ferrannini, Lars H Lund, Lina Benson, Manfredi Rizzo, Wael Almahmeed, Giuseppe M C Rosano, Gianluigi Savarese, Francesco Cosentino
Aims Type 2 diabetes (T2DM) in patients with coronavirus disease-19 (COVID-19) is associated with a worse prognosis. We separately investigated the associations between the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like pept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2983b3944021d51052860c709f785f6c
https://openaccess.sgul.ac.uk/id/eprint/114747/1/pvac044.pdf
https://openaccess.sgul.ac.uk/id/eprint/114747/1/pvac044.pdf
Publikováno v:
International journal of cardiology. 359
Publikováno v:
International Journal of Cardiology Cardiovascular Risk and Prevention. 15:200160
Background: The prevalence of diabetes mellitus is growing worldwide, showing almost a 10-fold increase in the last five decades. Despite advances in the understanding of the disease mechanisms, preventive measures, and treatment options, morbidity a
Autor:
Maciej Banach, Stanisław Surma, Zeljko Reiner, Niki Katsiki, Peter E. Penson, Zlatko Fras, Amirhossein Sahebkar, Francesco Paneni, Manfredi Rizzo, John Kastelein
Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e693607bd1c9fad2a5af1ff6597ddf1
Autor:
Wael Al Mahmeed, Khalid Al-Rasadi, Yajnavalka Banerjee, Antonio Ceriello, Francesco Cosentino, Massimo Galia, Su-Yen Goh, Peter Kempler, Nader Lessan, Nikolaos Papanas, Ali A. Rizvi, Raul D. Santos, Anca P. Stoian, Peter P. Toth, Manfredi Rizzo, The CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO)
Publikováno v:
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Efforts in the fight against COVID-19 are achieving success in many parts of the world, although progress remains slow in other regions. We believe that a syndemic approach needs to be adopted to address this pandemic given the strong apparent interp
Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!
Publikováno v:
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 34
Non-alcoholic fatty liver disease (NAFLD) is the most frequent hepatic disease globally. NAFLD patients are at an increased risk of both liver and cardiovascular morbidity and mortality, as well as all-cause death. NAFLD prevalence is rapidly increas
Publikováno v:
Journal of Cardiovascular Pharmacology
Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE